Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
ARCHIVE: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies
press releaseinvestorARCHIVE
ARCHIVE: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne TechnologiesJuly 11, 2024
ARCHIVE: CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investors
investorvideoARCHIVE
ARCHIVE: CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investorsJune 18, 2024
ARCHIVE: MDB Capital CEO and Invizyne board member, Chris Marlett, presents the Invizyne story and initial public offering (IPO) opportunity to investors via Zoom on June 11, 2024
investorvideoARCHIVE
ARCHIVE: MDB Capital CEO and Invizyne board member, Chris Marlett, presents the Invizyne story and initial public offering (IPO) opportunity to investors via Zoom on June 11, 2024June 11, 2024
ARCHIVE: The story of eXoZymes: Interview with Tyler Korman and Paul Opgenorth
videoscienceARCHIVE
ARCHIVE: The story of eXoZymes: Interview with Tyler Korman and Paul OpgenorthMay 22, 2024
ARCHIVE: Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
talentpress releaseARCHIVE
ARCHIVE: Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on NasdaqMay 7, 2024
ARCHIVE: Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on NasdaqFebruary 12, 2024
ARCHIVE: Michael Burns Joins Invizyne as Executive Vice President of Energy Transition
talentbiofuelARCHIVE
ARCHIVE: Michael Burns Joins Invizyne as Executive Vice President of Energy TransitionNovember 8, 2023
ARCHIVE: Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort
biofuelpress releaseARCHIVE
ARCHIVE: Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth CohortOctober 17, 2023
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy
biofuelpress release
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of EnergyOctober 11, 2023
ARCHIVE: A bio-inspired cell-free system for cannabinoid production from inexpensive inputs
sciencepublicationARCHIVE
ARCHIVE: A bio-inspired cell-free system for cannabinoid production from inexpensive inputsAugust 24, 2020
Previous page
Page 10 of 11
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark